Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients

Clinical Infectious Diseases

Volumn 45, Issue 4, 2007, Pages 439-447

  Li, Fanny ^a   Kenyon, Kenneth W ^a   Kirby, Katharine A ^b   Fishbein, Daniel P ^a   Boeckh, Michael ^a,b   Limaye, Ajit P ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; DACLIZUMAB; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; FEMALE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORGAN DONOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UL97 GENE; VIRUS GENE;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 34547645045     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519941     Document Type: Article

References (26)

1. Rubin RH. Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000; 19:731-5.
2. Macdonald PS, Keogh AM, Marshman D, et al. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant 1995; 14:32-8.
3. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326:1182-6.
4. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105-15.
5. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
6. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3:731-5.
7. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2:112-7.
8. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356:645-9.
9. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35:866-72.
10. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002; 17: 265-73.
11. Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999; 68:1272-9.
12. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir- resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21:1274-82.
13. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185:20-7.
14. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9:587-93.
15. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-7.
16. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81:1645-52.
17. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188:32-9.
18. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the ul97 and DNA polymerase genes. J Infect Dis 1997; 176:69-77.
19. 2004 Annual report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: transplant data 1994-2003. Rockville, MD: HHS/HRSA/HSBOT, UNOS, URREA, 2004.
20. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995; 123:18-26.
21. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7:166-70.
22. Falagas ME, Paya C, Ruthazer R, et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 1998; 66:1020-8.
23. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66:329-37.
24. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the international society for heart and lung transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005; 24: 945-55.
25. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261:3561-6.
26. Kirklin JK, Pambukian SV, McGiffin DC, Benza RL. Current outcomes following heart transplantation. Semin Thorac Cardiovasc Surg 2004; 16:395-403.